Aprogen pharmaceuticals,Inc. (003060.KS)
KRW 704.0
(-4.22%)
KRW 704.0
(-4.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -118.26 Billion KRW | -2218.15% |
| 2022 | 5.58 Billion KRW | -31.09% |
| 2021 | 8.1 Billion KRW | -57.17% |
| 2020 | 18.91 Billion KRW | 645.72% |
| 2019 | -3.46 Billion KRW | -185.21% |
| 2018 | -1.21 Billion KRW | 92.57% |
| 2017 | -16.36 Billion KRW | -317.71% |
| 2016 | -3.91 Billion KRW | -241.91% |
| 2015 | 2.76 Billion KRW | 171.02% |
| 2014 | -3.88 Billion KRW | 81.36% |
| 2013 | -20.85 Billion KRW | 16.16% |
| 2012 | -24.87 Billion KRW | -445.4% |
| 2011 | -4.56 Billion KRW | -547.36% |
| 2010 | -704.42 Million KRW | 91.3% |
| 2009 | -8.09 Billion KRW | -47.5% |
| 2008 | -5.48 Billion KRW | 47.7% |
| 2007 | -10.49 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -23.47 Billion KRW | -290.55% |
| 2024 Q1 | -6.01 Billion KRW | 93.79% |
| 2023 Q2 | -17.71 Billion KRW | -305.65% |
| 2023 Q3 | -4.85 Billion KRW | 72.57% |
| 2023 Q4 | -96.8 Billion KRW | -1891.99% |
| 2023 FY | -118.26 Billion KRW | -2218.15% |
| 2023 Q1 | 8.61 Billion KRW | 232.08% |
| 2022 FY | 5.58 Billion KRW | -31.09% |
| 2022 Q3 | 4.47 Billion KRW | 44.67% |
| 2022 Q4 | -6.52 Billion KRW | -245.78% |
| 2022 Q2 | 3.09 Billion KRW | 9.41% |
| 2022 Q1 | 2.82 Billion KRW | 58.76% |
| 2021 Q1 | 1.94 Billion KRW | 328.85% |
| 2021 Q2 | 1.69 Billion KRW | -13.03% |
| 2021 Q3 | 2.68 Billion KRW | 58.77% |
| 2021 FY | 8.1 Billion KRW | -57.17% |
| 2021 Q4 | 1.78 Billion KRW | -33.72% |
| 2020 Q2 | 3.77 Billion KRW | -0.49% |
| 2020 FY | 18.91 Billion KRW | 645.72% |
| 2020 Q4 | -849.93 Million KRW | -118.73% |
| 2020 Q3 | 4.53 Billion KRW | 20.26% |
| 2020 Q1 | 3.79 Billion KRW | 229.71% |
| 2019 Q3 | -1.9 Billion KRW | -222.92% |
| 2019 FY | -3.46 Billion KRW | -185.21% |
| 2019 Q2 | 1.55 Billion KRW | 130.85% |
| 2019 Q1 | -5.03 Billion KRW | -4.45% |
| 2019 Q4 | -2.92 Billion KRW | -53.1% |
| 2018 Q3 | 3.94 Billion KRW | 150.54% |
| 2018 FY | -1.21 Billion KRW | 92.57% |
| 2018 Q1 | -1.91 Billion KRW | -21.73% |
| 2018 Q2 | 1.57 Billion KRW | 182.25% |
| 2018 Q4 | -4.82 Billion KRW | -222.19% |
| 2017 Q2 | -3.18 Billion KRW | -55.42% |
| 2017 Q3 | -9.56 Billion KRW | -200.61% |
| 2017 FY | -16.36 Billion KRW | -317.71% |
| 2017 Q1 | -2.04 Billion KRW | 32.8% |
| 2017 Q4 | -1.57 Billion KRW | 83.55% |
| 2016 FY | -3.91 Billion KRW | -241.91% |
| 2016 Q1 | -11.97 Million KRW | -101.41% |
| 2016 Q4 | -3.04 Billion KRW | -327.95% |
| 2016 Q3 | -711.83 Million KRW | -382.17% |
| 2016 Q2 | -147.63 Million KRW | -1133.26% |
| 2015 Q2 | 1.75 Billion KRW | 1870.65% |
| 2015 Q3 | 252.23 Million KRW | -85.65% |
| 2015 FY | 2.76 Billion KRW | 171.02% |
| 2015 Q4 | 849.83 Million KRW | 236.92% |
| 2015 Q1 | -99.27 Million KRW | 86.5% |
| 2014 Q2 | -539.39 Million KRW | 57.83% |
| 2014 Q3 | -1.33 Billion KRW | -147.24% |
| 2014 FY | -3.88 Billion KRW | 81.36% |
| 2014 Q1 | -1.27 Billion KRW | 82.55% |
| 2014 Q4 | -735.4 Million KRW | 44.86% |
| 2013 Q4 | -7.32 Billion KRW | -351.02% |
| 2013 Q3 | -1.62 Billion KRW | 73.91% |
| 2013 FY | -20.85 Billion KRW | 16.16% |
| 2013 Q1 | -5.67 Billion KRW | 49.43% |
| 2013 Q2 | -6.22 Billion KRW | -9.82% |
| 2012 Q4 | -11.21 Billion KRW | -1556.73% |
| 2012 Q1 | -2.55 Billion KRW | 0.0% |
| 2012 Q2 | -9.23 Billion KRW | -261.2% |
| 2012 Q3 | -676.83 Million KRW | 92.67% |
| 2012 FY | -24.87 Billion KRW | -445.4% |
| 2011 Q1 | 582.89 Million KRW | 0.0% |
| 2011 Q2 | 98.78 Million KRW | -83.05% |
| 2011 Q3 | -1.96 Billion KRW | -2084.35% |
| 2011 FY | -4.56 Billion KRW | -547.36% |
| 2011 Q4 | - KRW | 100.0% |
| 2010 Q3 | - KRW | -100.0% |
| 2010 Q1 | 290 Million KRW | 499.58% |
| 2010 FY | -704.42 Million KRW | 91.3% |
| 2010 Q2 | 2.17 Billion KRW | 650.62% |
| 2009 FY | -8.09 Billion KRW | -47.5% |
| 2009 Q3 | - KRW | -100.0% |
| 2009 Q1 | 1.5 Billion KRW | 344.93% |
| 2009 Q2 | 1.18 Billion KRW | -21.28% |
| 2009 Q4 | 48.36 Million KRW | 0.0% |
| 2008 Q4 | -615.41 Million KRW | 0.0% |
| 2008 Q3 | - KRW | 100.0% |
| 2008 FY | -5.48 Billion KRW | 47.7% |
| 2008 Q2 | -2.01 Billion KRW | 77.23% |
| 2008 Q1 | -8.83 Billion KRW | -1302.58% |
| 2007 Q3 | -8.91 Billion KRW | -1826.05% |
| 2007 Q2 | -463 Million KRW | 21.87% |
| 2007 Q1 | -592.61 Million KRW | 0.0% |
| 2007 FY | -10.49 Billion KRW | 0.0% |
| 2007 Q4 | -630.12 Million KRW | 92.93% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -1547.004% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 303.95% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | -98.483% |
| HANDOK Inc. | -28.79 Billion KRW | -310.695% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | -1305.432% |
| Yuhan Corporation | 93.5 Billion KRW | 226.479% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 1163.341% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | -376.663% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 180.879% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | 3470.845% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -4618.682% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | -5602.743% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | -2513.789% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 629.579% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -1547.004% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | -464.779% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | 3400.514% |
| JW Holdings Corporation | 19.02 Billion KRW | 721.612% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | -49.845% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 155.651% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 419.593% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -106.313% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | 2031.956% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | 7209.523% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | 2463.152% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | -1547.004% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 419.946% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 206.07% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 419.593% |
| Yuhan Corporation | 93.5 Billion KRW | 226.479% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | -627.825% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | -2951.694% |
| Suheung Co., Ltd. | 6.11 Billion KRW | 2032.756% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 419.593% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 725.574% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 345.059% |
| CKD Bio Corp. | -24.19 Billion KRW | -388.869% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 594.502% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 531.039% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 497.221% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | -106.313% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 351.598% |
| Boryung Corporation | 40.2 Billion KRW | 394.183% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | -277.501% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | -4618.682% |
| JW Lifescience Corporation | 28.14 Billion KRW | 520.231% |